A validated and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA virus neutralising antibodies for vaccine development and comparison [version 2; peer review: 2 approved]
Background Over the past few decades, World Health Organization (WHO) has made massive efforts to promote the development of a vaccine against Lassa virus (LASV), one of the top ten priority pathogens for research and development under the WHO R&D Blueprint for Emerging Infections. To date, seve...
Saved in:
| Main Authors: | Alessandro Manenti, Emanuele Montomoli, Francesca Dapporto, Maria Altamura, Nigel Temperton, Pietro Piu, Claudia Semplici, Eleonora Molesti, Vittoria Forconi, Roberta Antonelli |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2024-10-01
|
| Series: | F1000Research |
| Subjects: | |
| Online Access: | https://f1000research.com/articles/13-534/v2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lassa virus in novel hosts: insights into the epidemiology of lassa virus infections in southern Nigeria
by: Anise Nkenjop Happi, et al.
Published: (2024-12-01) -
Inoculation route-dependent Lassa virus dissemination and shedding dynamics in the natural reservoir – Mastomys natalensis
by: D. M. Wozniak, et al.
Published: (2021-01-01) -
The epidemiology of Lassa fever in Ghana: a study on the 2023 Lassa fever outbreak in Ghana
by: Kwasi Atweri Akowuah, et al.
Published: (2025-04-01) -
Lassa fever in Benin: description of the 2014 and 2016 epidemics and genetic characterization of a new Lassa virus
by: Anges Yadouleton, et al.
Published: (2020-01-01) -
Mapping the antibody response to Lassa virus vaccination of non-human primatesResearch in context
by: Adrian S. Enriquez, et al.
Published: (2025-04-01)